Affordable Access

Access to the full text

Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer

Authors
  • Yamamoto, Takehito1
  • Kawada, Kenji1
  • Hida, Koya1
  • Matsusue, Ryo2
  • Itatani, Yoshiro1
  • Mizuno, Rei1
  • Yamaguchi, Takashi2
  • Ikai, Iwao2
  • Sakai, Yoshiharu1
  • 1 Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto, 606-8507, Japan , Kyoto (Japan)
  • 2 National Hospital Organization, Kyoto Medical Center, Kyoto, Japan , Kyoto (Japan)
Type
Published Article
Journal
Scientific Reports
Publisher
Springer Nature
Publication Date
Mar 03, 2021
Volume
11
Issue
1
Identifiers
DOI: 10.1038/s41598-021-84475-4
Source
Springer Nature
License
Green

Abstract

Although numerous studies have highlighted the prognostic values of various inflammation-related markers, clinical significance remains to be elucidated. The prognostic values of inflammation-related biomarkers for rectal cancer were investigated in this study. A total of 448 patients with stage II/III rectal cancer undergoing curative resection were enrolled from the discovery cohort (n = 240) and validation cohort (n = 208). We comprehensively compared the prognostic values of 11 inflammation-related markers-derived from neutrophil, lymphocyte, platelet, monocyte, albumin, and C-reactive protein for overall survival (OS) and recurrence-free survival (RFS). Among 11 inflammation-related markers, only “lymphocyte × albumin (LA)” was significantly associated with both OS and RFS in the discovery cohort (P = 0.007 and 0.015, respectively). Multivariate analysis indicated that low LA was significantly associated with poor OS (hazard ratio [HR] 2.19, 95% confidence interval [CI] 1.09–4.58, P = 0.025), and poor RFS (HR 1.61, 95% CI 1.01–2.80, P = 0.048). Furthermore, using the discovery cohort, we confirmed that low LA was significantly associated with poor OS (HR 2.89, 95% CI 1.42–6.00, P = 0.002), and poor RFS (HR 1.79, 95% CI 1.04–2.95, P = 0.034). LA can be a novel prognostic biomarker for stage II/III rectal cancer.

Report this publication

Statistics

Seen <100 times